One thing that I did get from today's call was that this drug is tricky to manufacture. I think NP said that he *had* to get Dr. Nitya Ray back because they were struggling to get more of the drug produced after he had left the company.

It also sounds like MAB production lines take some time to get set up and there is a long wait from that bioprocess article.

Again, this is not my field, but perhaps these two points should at least give us some confidence that this isn't all that easy to do.